<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35034585</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2222-1751</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Emerging microbes &amp; infections</Title>
          <ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antibiotic resistance in hospital-acquired ESKAPE-E infections in low- and lower-middle-income countries: a systematic review and meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>443</StartPage>
          <EndPage>451</EndPage>
          <MedlinePgn>443-451</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2022.2030196</ELocationID>
        <Abstract>
          <AbstractText>Antimicrobial resistance (AMR) and hospital-acquired infections (HAIs) are global health challenges. The burden of antibiotic resistance in HAIs is still unclear in low- and lower-middle-income countries (L-LMICs). This study summarizes recent data on antibiotic resistance in priority HAIs (ESKAPE-E) in L-LMICs and compares them with data from high-income countries (HICs). EMBASE, Web of Science, and Global Index Medicus were searched for studies on AMR patterns in HAIs published from 01/2010 to 10/2020. Random-effects meta-analyses were performed to obtain pooled estimates. In total, 163 eligible studies were included in the review and meta-analysis. The pooled methicillin resistance proportion in <i>Staphylococcus aureus</i> was 48.4% (95% confidence interval [95%CI] 41·7-55·2, n = 80). Pooled carbapenem resistance proportions were high in Gram-negative pathogens: <i>Escherichia coli</i>: 16·6% (95%CI 10·7-23·4, n = 60); <i>Klebsiella pneumoniae</i>: 34·9% (95%CI 24·6-45·9, n = 50); <i>Pseudomonas aeruginosa</i>: 37.1% (95%CI 24·6-45·9, n = 56); <i>Enterobacter</i> spp.: 51·2% (95%CI 27·5-74·7, n = 7); and <i>Acinetobacter baumannii (complex):</i> 72·4% (95%CI 62·1-81·7%, n = 36). A higher resistance proportions were observed for third-generation cephalosporins: <i>Klebsiella pneumoniae</i>: 78·7% (95%CI 71·5-85·2, n = 46); <i>Escherichia coli:</i> 78·5% (95%CI 72·1-84·2%, n = 58); and <i>Enterobacter</i> spp.: 83·5% (95%CI 71·9-92·8, n = 8). We observed a high between-study heterogeneity (I<sup>2</sup>  &gt;  80%), which could not be explained by our set of moderators. Pooled resistance proportions for Gram-negative pathogens were higher in L-LMICs than regional and national estimates from HICs. Patients in resource-constrained regions are particularly affected by AMR. To combat the high resistance to critical antibiotics in L-LMICs, and bridge disparities in health, it is crucial to strengthen local surveillance and the health systems in general.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ayobami</LastName>
            <ForeName>Olaniyi</ForeName>
            <Initials>O</Initials>
            <Identifier Source="ORCID">0000-0003-1480-386X</Identifier>
            <AffiliationInfo>
              <Affiliation>Unit for Healthcare Associated Infections, Surveillance of Antimicrobial Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brinkwirth</LastName>
            <ForeName>Simon</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Unit for Healthcare Associated Infections, Surveillance of Antimicrobial Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eckmanns</LastName>
            <ForeName>Tim</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Unit for Healthcare Associated Infections, Surveillance of Antimicrobial Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Markwart</LastName>
            <ForeName>Robby</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0003-0338-3433</Identifier>
            <AffiliationInfo>
              <Affiliation>Unit for Healthcare Associated Infections, Surveillance of Antimicrobial Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jena University Hospital, Institute of General Practice and Family Medicine, Jena, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Emerg Microbes Infect</MedlineTA>
        <NlmUniqueID>101594885</NlmUniqueID>
        <ISSNLinking>2222-1751</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D040981" MajorTopicYN="Y">Acinetobacter baumannii</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003906" MajorTopicYN="Y">Developing Countries</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024881" MajorTopicYN="N">Drug Resistance, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007711" MajorTopicYN="N">Klebsiella pneumoniae</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antibiotic resistance</Keyword>
        <Keyword MajorTopicYN="N">Health equity</Keyword>
        <Keyword MajorTopicYN="N">hospital-acquired infections</Keyword>
        <Keyword MajorTopicYN="N">low-resource countries</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35034585</ArticleId>
        <ArticleId IdType="pmc">PMC8820817</ArticleId>
        <ArticleId IdType="doi">10.1080/22221751.2022.2030196</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ahmad M, Khan AU.. 
Global economic impact of antibiotic resistance: a review. J Glob Antimicrob Resist. 2019;19:313–316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31176071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tacconelli E, Carrara E, Savoldi A, et al. . 
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar;18(3):318–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29276051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabah A, Koulenti D, Laupland K, et al. . 
Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International cohort study. Intensive Care Med. 2012;38(12):1930–1945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23011531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laxminarayan R, Matsoso P, Pant S, et al. . 
Access to effective antimicrobials: a worldwide challenge. Lancet. 2016 Jan 9;387(10014):168–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26603918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allegranzi B, Bagheri Nejad S, Combescure C, et al. . 
Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011 Jan 15;377(9761):228–241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21146207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. . 
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Research ed)
2021;2021(372):n71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8005924</ArticleId>
            <ArticleId IdType="pubmed">33782057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Bank . World Bank country and lending groups 2021; 2021 Aug 20. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.</Citation>
        </Reference>
        <Reference>
          <Citation>Cochrane Community . Covidence 2020; 2020 Oct 23. Available from: https://community.cochrane.org/help/tools-and-software/covidence.</Citation>
        </Reference>
        <Reference>
          <Citation>Barendregt JJ, Doi SA, Lee YY, et al. . 
Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23963506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Houwelingen HC, Arends LR, Stijnen T.. 
Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002 Feb 28;21(4):589–624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11836738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Team RC . R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021 [cited 2021 August 24]. Available from: http://www.R-project.org.</Citation>
        </Reference>
        <Reference>
          <Citation>Guido Schwarzer JRC, Rücker G.. 
Meta-analysis with R. Springer International Publishing. Basel; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Viechtbauer W.
Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.</Citation>
        </Reference>
        <Reference>
          <Citation>Ahoyo TA, Bankole HS, Adeoti FM, et al. . 
Prevalence of nosocomial infections and anti-infective therapy in Benin: results of the first nationwide survey in 2012. Antimicrob Resist Infect Control. 2014;3. 10.1186/2047-2994-3-17</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2047-2994-3-17</ArticleId>
            <ArticleId IdType="pmc">PMC4039045</ArticleId>
            <ArticleId IdType="pubmed">24883183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labi AK, Obeng-Nkrumah N, Owusu E, et al. . 
Multi-centre point-prevalence survey of hospital-acquired infections in Ghana. J Hosp Infect. 2019;101(1):60–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29730140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agmy G, Mohamed S, Gad Y, et al. . 
Bacterial profile, antibiotic sensitivity and resistance of lower respiratory tract infections in upper Egypt. Mediterr J Hematol Infect Dis. 2013;5(1):1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3787711</ArticleId>
            <ArticleId IdType="pubmed">24106606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed F, Fayza F. Bacterial pattern and risk factors of hospital acquired infections in a tertiary care hospital, Egypt. 2018. p. 9–16.</Citation>
        </Reference>
        <Reference>
          <Citation>Amutha B, Viswanathan T.. 
Incidences of staphylococcus species in surgical site infections-prospective study from tertiary care center, Coimbatore. Tamilnadu. Int J Pharm Pharm Sci. 2015;7(5):225–228.</Citation>
        </Reference>
        <Reference>
          <Citation>Bhadade R, Harde M, desouza R, et al. . 
Emerging Trends of Nosocomial pneumonia in intensive care unit of a tertiary care public teaching hospital in Western India. Ann Afr Med. 2017;16(3):107–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5579893</ArticleId>
            <ArticleId IdType="pubmed">28671150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Sahrigy SAF, Shouman MG, Ibrahim HM, et al. . 
Prevalence and anti-microbial susceptibility of hospital acquired infections in two pediatric intensive care units in Egypt. Open Access Macedonian J Med Sci. 2019;7(11):1744–1749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6614260</ArticleId>
            <ArticleId IdType="pubmed">31316652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moemen D, Tawfeek D, Badawy W.. 
Healthcare-associated vancomycin resistant Enterococcus faecium; infections in the Mansoura University Hospitals intensive care units, Egypt. Braz j Microbiol. 2015;46(3):777–783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4568866</ArticleId>
            <ArticleId IdType="pubmed">26413060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Mekes A, Zahlane K, Said LA, et al. . 
The clinical and epidemiological risk factors of infections due to multi-drug resistant bacteria in an adult intensive care unit of University Hospital Center in Marrakesh-Morocco. J Infect Public Health. 2020;13(4):637–643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31537511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peters L, Olson L, Khu DTK, et al. . 
Multiple antibiotic resistance as a risk factor for mortality and prolonged hospital stay: a cohort study among neonatal intensive care patients with hospital-acquired infections caused by Gram-negative bacteria in Vietnam. Plos One. 2019;14(5).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6505890</ArticleId>
            <ArticleId IdType="pubmed">31067232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaari A, Mnif B, Bahloul M, et al. . 
Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int J Infect Dis. 2013;17(12):E1225–E1228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24094525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vijayanarayana K, Rau NR, Naik NA, et al. . 
An appraisal of sensitivity and resistance pattern of organisms isolated from hospital acquired pneumonia patients. research. J Pharm Biol Chem Sci. 2014;5(4):384–398.</Citation>
        </Reference>
        <Reference>
          <Citation>Klein EY, Van Boeckel TP, Martinez EM, et al. . 
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018;115(15):E3463–E3470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5899442</ArticleId>
            <ArticleId IdType="pubmed">29581252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Global antimicrobial resistance and use surveillance system (GLASS) report 2021. Geneva: WHO; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Antimicrobial resistance global report on surveillance: 2014 summary. World Health Organization. Geneva; 2014.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organisation . WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: WHO; 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Klein EY, Milkowska-Shibata M, Tseng KK, et al. . 
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data. Lancet Infect Dis. 2021;21(1):107–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32717205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mbwasi R, Mapunjo S, Wittenauer R, et al. . 
National consumption of antimicrobials in Tanzania: 2017-2019. Front Pharmacol. 2020;11:1667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7662556</ArticleId>
            <ArticleId IdType="pubmed">33192526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nordmann P, Naas T, Poirel L.. 
Global spread of carbapenemase-producing enterobacteriaceae. Emerg Infect Dis. 2011 Oct;17(10):1791–1798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3310682</ArticleId>
            <ArticleId IdType="pubmed">22000347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laxminarayan R, Duse A, Wattal C, et al. . 
Antibiotic resistance — the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–1098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24252483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox JA, Vlieghe E, Mendelson M, et al. . 
Antibiotic stewardship in low- and middle-income countries: the same but different?
Clin Microbiol Infect. 2017;23(11):812–818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28712667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broccoli MC, Pigoga JL, Nyirenda M, et al. . 
Essential medicines for emergency care in Africa. Afr J Emerg Med. 2018;8(3):110–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6223583</ArticleId>
            <ArticleId IdType="pubmed">30456159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tartari E, Tomczyk S, Pires D, et al. . 
Implementation of the infection prevention and control core components at the national level: a global situational analysis. J Hosp Infect. 2021;108:94–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7884929</ArticleId>
            <ArticleId IdType="pubmed">33271215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H, Yoon E-J, Kim D, et al. . 
Antimicrobial resistance of major clinical pathogens in South Korea, May 2016 to April 2017: first one-year report from Kor-GLASS. Eurosurveillance. 2018;23(42):1800047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6199864</ArticleId>
            <ArticleId IdType="pubmed">30352640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ham DC, See I, Novosad S, et al. . 
Investigation of hospital-onset methicillin-resistant Staphylococcus aureus bloodstream infections at eight high burden acute care facilities in the United States, 2016. J Hosp Infect. 2020 Apr 10;105:502–508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7857529</ArticleId>
            <ArticleId IdType="pubmed">32283173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Centre for Disease Prevention and Control . Antimicrobial resistance in the EU/EEA (EARS-Net): annual epidemiological report for 2019. Stockholm: ECDC; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Unni S, Siddiqui TJ, Bidaisee S.. 
Reduced Susceptibility and resistance to vancomycin of Staphylococcus aureus: a review of global Incidence patterns and related genetic mechanisms. Cureus. 2021;13(10):e18925–e18925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8603868</ArticleId>
            <ArticleId IdType="pubmed">34812309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention . Antibiotic resistance &amp; patient safety portal: antibiotic resistance. Atlanta: CDC; 2021 Aug 29; Available from: https://arpsp.cdc.gov/profile/antibiotic-resistance?tab = antibiotic-resistance.</Citation>
        </Reference>
        <Reference>
          <Citation>Japanese Ministry of Health Law . Japan Nosocomial Infections Surveillance (JANIS): annual open report 2020. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Liang Y, Qiu L, Zheng X, et al. . 
Trend in antimicrobial resistance of Staphylococcus aureus: results from the China Antimicrobial surveillance Network (CHINET) in the last 15-year-period reports (2005-2019). Infect Drug Resist. 2021;14:2179–2181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8203196</ArticleId>
            <ArticleId IdType="pubmed">34140786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayobami O, Willrich N, Reuss A, et al. . 
The ongoing challenge of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological analysis of bloodstream infections. Emerg Microbes Infect. 2020;9(1):1180–1193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7448851</ArticleId>
            <ArticleId IdType="pubmed">32498615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markwart R, Saito H, Harder T, et al. . 
Epidemiology and burden of sepsis acquired in hospitals and intensive care units: a systematic review and meta-analysis. Intensive Care Med. 2020 Aug;46(8):1536–1551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7381455</ArticleId>
            <ArticleId IdType="pubmed">32591853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brinkwirth S, Ayobami O, Eckmanns T, et al. . 
Hospital-acquired infections caused by enterococci: a systematic review and meta-analysis, WHO European region, 1 January 2010 to 4 February 2020. Eurosurveillance. 2021;26(45):2001628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8646982</ArticleId>
            <ArticleId IdType="pubmed">34763754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collignon P, Beggs JJ, Walsh TR, et al. . 
Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. The Lancet Planetary Health. 2018;2(9):e398–e405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30177008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphries RM, Abbott AN, Hindler JA.. 
Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories. J Clin Microbiol. 2019;57(6):e00203–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6535595</ArticleId>
            <ArticleId IdType="pubmed">30971460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Global action plan on antimicrobial resistance. Geneva; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Pan American Health Organization . Latin American network for antimicrobial resistance surveillance (RELAVRA): AMR trends analysis. Washington (DC: ): PAHO; 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Hu F, Zhu D, Wang F, et al. . 
Current status and trends of antibacterial resistance in China. Clin Infect Dis. 2018 Nov 13;67(suppl_2):S128–S134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30423045</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35034585</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2222-1751</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Emerging microbes &amp; infections</Title>
          <ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antibiotic resistance in hospital-acquired ESKAPE-E infections in low- and lower-middle-income countries: a systematic review and meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>443</StartPage>
          <EndPage>451</EndPage>
          <MedlinePgn>443-451</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2022.2030196</ELocationID>
        <Abstract>
          <AbstractText>Antimicrobial resistance (AMR) and hospital-acquired infections (HAIs) are global health challenges. The burden of antibiotic resistance in HAIs is still unclear in low- and lower-middle-income countries (L-LMICs). This study summarizes recent data on antibiotic resistance in priority HAIs (ESKAPE-E) in L-LMICs and compares them with data from high-income countries (HICs). EMBASE, Web of Science, and Global Index Medicus were searched for studies on AMR patterns in HAIs published from 01/2010 to 10/2020. Random-effects meta-analyses were performed to obtain pooled estimates. In total, 163 eligible studies were included in the review and meta-analysis. The pooled methicillin resistance proportion in <i>Staphylococcus aureus</i> was 48.4% (95% confidence interval [95%CI] 41·7-55·2, n = 80). Pooled carbapenem resistance proportions were high in Gram-negative pathogens: <i>Escherichia coli</i>: 16·6% (95%CI 10·7-23·4, n = 60); <i>Klebsiella pneumoniae</i>: 34·9% (95%CI 24·6-45·9, n = 50); <i>Pseudomonas aeruginosa</i>: 37.1% (95%CI 24·6-45·9, n = 56); <i>Enterobacter</i> spp.: 51·2% (95%CI 27·5-74·7, n = 7); and <i>Acinetobacter baumannii (complex):</i> 72·4% (95%CI 62·1-81·7%, n = 36). A higher resistance proportions were observed for third-generation cephalosporins: <i>Klebsiella pneumoniae</i>: 78·7% (95%CI 71·5-85·2, n = 46); <i>Escherichia coli:</i> 78·5% (95%CI 72·1-84·2%, n = 58); and <i>Enterobacter</i> spp.: 83·5% (95%CI 71·9-92·8, n = 8). We observed a high between-study heterogeneity (I<sup>2</sup>  &gt;  80%), which could not be explained by our set of moderators. Pooled resistance proportions for Gram-negative pathogens were higher in L-LMICs than regional and national estimates from HICs. Patients in resource-constrained regions are particularly affected by AMR. To combat the high resistance to critical antibiotics in L-LMICs, and bridge disparities in health, it is crucial to strengthen local surveillance and the health systems in general.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ayobami</LastName>
            <ForeName>Olaniyi</ForeName>
            <Initials>O</Initials>
            <Identifier Source="ORCID">0000-0003-1480-386X</Identifier>
            <AffiliationInfo>
              <Affiliation>Unit for Healthcare Associated Infections, Surveillance of Antimicrobial Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brinkwirth</LastName>
            <ForeName>Simon</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Unit for Healthcare Associated Infections, Surveillance of Antimicrobial Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eckmanns</LastName>
            <ForeName>Tim</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Unit for Healthcare Associated Infections, Surveillance of Antimicrobial Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Markwart</LastName>
            <ForeName>Robby</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0003-0338-3433</Identifier>
            <AffiliationInfo>
              <Affiliation>Unit for Healthcare Associated Infections, Surveillance of Antimicrobial Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jena University Hospital, Institute of General Practice and Family Medicine, Jena, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Emerg Microbes Infect</MedlineTA>
        <NlmUniqueID>101594885</NlmUniqueID>
        <ISSNLinking>2222-1751</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D040981" MajorTopicYN="Y">Acinetobacter baumannii</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003906" MajorTopicYN="Y">Developing Countries</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024881" MajorTopicYN="N">Drug Resistance, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007711" MajorTopicYN="N">Klebsiella pneumoniae</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antibiotic resistance</Keyword>
        <Keyword MajorTopicYN="N">Health equity</Keyword>
        <Keyword MajorTopicYN="N">hospital-acquired infections</Keyword>
        <Keyword MajorTopicYN="N">low-resource countries</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35034585</ArticleId>
        <ArticleId IdType="pmc">PMC8820817</ArticleId>
        <ArticleId IdType="doi">10.1080/22221751.2022.2030196</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ahmad M, Khan AU.. 
Global economic impact of antibiotic resistance: a review. J Glob Antimicrob Resist. 2019;19:313–316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31176071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tacconelli E, Carrara E, Savoldi A, et al. . 
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar;18(3):318–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29276051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabah A, Koulenti D, Laupland K, et al. . 
Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International cohort study. Intensive Care Med. 2012;38(12):1930–1945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23011531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laxminarayan R, Matsoso P, Pant S, et al. . 
Access to effective antimicrobials: a worldwide challenge. Lancet. 2016 Jan 9;387(10014):168–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26603918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allegranzi B, Bagheri Nejad S, Combescure C, et al. . 
Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011 Jan 15;377(9761):228–241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21146207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. . 
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Research ed)
2021;2021(372):n71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8005924</ArticleId>
            <ArticleId IdType="pubmed">33782057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Bank . World Bank country and lending groups 2021; 2021 Aug 20. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.</Citation>
        </Reference>
        <Reference>
          <Citation>Cochrane Community . Covidence 2020; 2020 Oct 23. Available from: https://community.cochrane.org/help/tools-and-software/covidence.</Citation>
        </Reference>
        <Reference>
          <Citation>Barendregt JJ, Doi SA, Lee YY, et al. . 
Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23963506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Houwelingen HC, Arends LR, Stijnen T.. 
Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002 Feb 28;21(4):589–624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11836738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Team RC . R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021 [cited 2021 August 24]. Available from: http://www.R-project.org.</Citation>
        </Reference>
        <Reference>
          <Citation>Guido Schwarzer JRC, Rücker G.. 
Meta-analysis with R. Springer International Publishing. Basel; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Viechtbauer W.
Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.</Citation>
        </Reference>
        <Reference>
          <Citation>Ahoyo TA, Bankole HS, Adeoti FM, et al. . 
Prevalence of nosocomial infections and anti-infective therapy in Benin: results of the first nationwide survey in 2012. Antimicrob Resist Infect Control. 2014;3. 10.1186/2047-2994-3-17</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2047-2994-3-17</ArticleId>
            <ArticleId IdType="pmc">PMC4039045</ArticleId>
            <ArticleId IdType="pubmed">24883183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labi AK, Obeng-Nkrumah N, Owusu E, et al. . 
Multi-centre point-prevalence survey of hospital-acquired infections in Ghana. J Hosp Infect. 2019;101(1):60–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29730140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agmy G, Mohamed S, Gad Y, et al. . 
Bacterial profile, antibiotic sensitivity and resistance of lower respiratory tract infections in upper Egypt. Mediterr J Hematol Infect Dis. 2013;5(1):1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3787711</ArticleId>
            <ArticleId IdType="pubmed">24106606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed F, Fayza F. Bacterial pattern and risk factors of hospital acquired infections in a tertiary care hospital, Egypt. 2018. p. 9–16.</Citation>
        </Reference>
        <Reference>
          <Citation>Amutha B, Viswanathan T.. 
Incidences of staphylococcus species in surgical site infections-prospective study from tertiary care center, Coimbatore. Tamilnadu. Int J Pharm Pharm Sci. 2015;7(5):225–228.</Citation>
        </Reference>
        <Reference>
          <Citation>Bhadade R, Harde M, desouza R, et al. . 
Emerging Trends of Nosocomial pneumonia in intensive care unit of a tertiary care public teaching hospital in Western India. Ann Afr Med. 2017;16(3):107–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5579893</ArticleId>
            <ArticleId IdType="pubmed">28671150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Sahrigy SAF, Shouman MG, Ibrahim HM, et al. . 
Prevalence and anti-microbial susceptibility of hospital acquired infections in two pediatric intensive care units in Egypt. Open Access Macedonian J Med Sci. 2019;7(11):1744–1749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6614260</ArticleId>
            <ArticleId IdType="pubmed">31316652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moemen D, Tawfeek D, Badawy W.. 
Healthcare-associated vancomycin resistant Enterococcus faecium; infections in the Mansoura University Hospitals intensive care units, Egypt. Braz j Microbiol. 2015;46(3):777–783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4568866</ArticleId>
            <ArticleId IdType="pubmed">26413060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Mekes A, Zahlane K, Said LA, et al. . 
The clinical and epidemiological risk factors of infections due to multi-drug resistant bacteria in an adult intensive care unit of University Hospital Center in Marrakesh-Morocco. J Infect Public Health. 2020;13(4):637–643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31537511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peters L, Olson L, Khu DTK, et al. . 
Multiple antibiotic resistance as a risk factor for mortality and prolonged hospital stay: a cohort study among neonatal intensive care patients with hospital-acquired infections caused by Gram-negative bacteria in Vietnam. Plos One. 2019;14(5).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6505890</ArticleId>
            <ArticleId IdType="pubmed">31067232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaari A, Mnif B, Bahloul M, et al. . 
Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int J Infect Dis. 2013;17(12):E1225–E1228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24094525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vijayanarayana K, Rau NR, Naik NA, et al. . 
An appraisal of sensitivity and resistance pattern of organisms isolated from hospital acquired pneumonia patients. research. J Pharm Biol Chem Sci. 2014;5(4):384–398.</Citation>
        </Reference>
        <Reference>
          <Citation>Klein EY, Van Boeckel TP, Martinez EM, et al. . 
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018;115(15):E3463–E3470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5899442</ArticleId>
            <ArticleId IdType="pubmed">29581252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Global antimicrobial resistance and use surveillance system (GLASS) report 2021. Geneva: WHO; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Antimicrobial resistance global report on surveillance: 2014 summary. World Health Organization. Geneva; 2014.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organisation . WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: WHO; 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Klein EY, Milkowska-Shibata M, Tseng KK, et al. . 
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data. Lancet Infect Dis. 2021;21(1):107–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32717205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mbwasi R, Mapunjo S, Wittenauer R, et al. . 
National consumption of antimicrobials in Tanzania: 2017-2019. Front Pharmacol. 2020;11:1667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7662556</ArticleId>
            <ArticleId IdType="pubmed">33192526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nordmann P, Naas T, Poirel L.. 
Global spread of carbapenemase-producing enterobacteriaceae. Emerg Infect Dis. 2011 Oct;17(10):1791–1798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3310682</ArticleId>
            <ArticleId IdType="pubmed">22000347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laxminarayan R, Duse A, Wattal C, et al. . 
Antibiotic resistance — the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–1098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24252483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox JA, Vlieghe E, Mendelson M, et al. . 
Antibiotic stewardship in low- and middle-income countries: the same but different?
Clin Microbiol Infect. 2017;23(11):812–818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28712667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broccoli MC, Pigoga JL, Nyirenda M, et al. . 
Essential medicines for emergency care in Africa. Afr J Emerg Med. 2018;8(3):110–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6223583</ArticleId>
            <ArticleId IdType="pubmed">30456159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tartari E, Tomczyk S, Pires D, et al. . 
Implementation of the infection prevention and control core components at the national level: a global situational analysis. J Hosp Infect. 2021;108:94–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7884929</ArticleId>
            <ArticleId IdType="pubmed">33271215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H, Yoon E-J, Kim D, et al. . 
Antimicrobial resistance of major clinical pathogens in South Korea, May 2016 to April 2017: first one-year report from Kor-GLASS. Eurosurveillance. 2018;23(42):1800047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6199864</ArticleId>
            <ArticleId IdType="pubmed">30352640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ham DC, See I, Novosad S, et al. . 
Investigation of hospital-onset methicillin-resistant Staphylococcus aureus bloodstream infections at eight high burden acute care facilities in the United States, 2016. J Hosp Infect. 2020 Apr 10;105:502–508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7857529</ArticleId>
            <ArticleId IdType="pubmed">32283173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Centre for Disease Prevention and Control . Antimicrobial resistance in the EU/EEA (EARS-Net): annual epidemiological report for 2019. Stockholm: ECDC; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Unni S, Siddiqui TJ, Bidaisee S.. 
Reduced Susceptibility and resistance to vancomycin of Staphylococcus aureus: a review of global Incidence patterns and related genetic mechanisms. Cureus. 2021;13(10):e18925–e18925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8603868</ArticleId>
            <ArticleId IdType="pubmed">34812309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention . Antibiotic resistance &amp; patient safety portal: antibiotic resistance. Atlanta: CDC; 2021 Aug 29; Available from: https://arpsp.cdc.gov/profile/antibiotic-resistance?tab = antibiotic-resistance.</Citation>
        </Reference>
        <Reference>
          <Citation>Japanese Ministry of Health Law . Japan Nosocomial Infections Surveillance (JANIS): annual open report 2020. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Liang Y, Qiu L, Zheng X, et al. . 
Trend in antimicrobial resistance of Staphylococcus aureus: results from the China Antimicrobial surveillance Network (CHINET) in the last 15-year-period reports (2005-2019). Infect Drug Resist. 2021;14:2179–2181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8203196</ArticleId>
            <ArticleId IdType="pubmed">34140786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayobami O, Willrich N, Reuss A, et al. . 
The ongoing challenge of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological analysis of bloodstream infections. Emerg Microbes Infect. 2020;9(1):1180–1193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7448851</ArticleId>
            <ArticleId IdType="pubmed">32498615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markwart R, Saito H, Harder T, et al. . 
Epidemiology and burden of sepsis acquired in hospitals and intensive care units: a systematic review and meta-analysis. Intensive Care Med. 2020 Aug;46(8):1536–1551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7381455</ArticleId>
            <ArticleId IdType="pubmed">32591853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brinkwirth S, Ayobami O, Eckmanns T, et al. . 
Hospital-acquired infections caused by enterococci: a systematic review and meta-analysis, WHO European region, 1 January 2010 to 4 February 2020. Eurosurveillance. 2021;26(45):2001628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8646982</ArticleId>
            <ArticleId IdType="pubmed">34763754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collignon P, Beggs JJ, Walsh TR, et al. . 
Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. The Lancet Planetary Health. 2018;2(9):e398–e405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30177008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphries RM, Abbott AN, Hindler JA.. 
Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories. J Clin Microbiol. 2019;57(6):e00203–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6535595</ArticleId>
            <ArticleId IdType="pubmed">30971460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Global action plan on antimicrobial resistance. Geneva; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Pan American Health Organization . Latin American network for antimicrobial resistance surveillance (RELAVRA): AMR trends analysis. Washington (DC: ): PAHO; 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Hu F, Zhu D, Wang F, et al. . 
Current status and trends of antibacterial resistance in China. Clin Infect Dis. 2018 Nov 13;67(suppl_2):S128–S134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30423045</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35034585</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2222-1751</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Emerging microbes &amp; infections</Title>
          <ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antibiotic resistance in hospital-acquired ESKAPE-E infections in low- and lower-middle-income countries: a systematic review and meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>443</StartPage>
          <EndPage>451</EndPage>
          <MedlinePgn>443-451</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2022.2030196</ELocationID>
        <Abstract>
          <AbstractText>Antimicrobial resistance (AMR) and hospital-acquired infections (HAIs) are global health challenges. The burden of antibiotic resistance in HAIs is still unclear in low- and lower-middle-income countries (L-LMICs). This study summarizes recent data on antibiotic resistance in priority HAIs (ESKAPE-E) in L-LMICs and compares them with data from high-income countries (HICs). EMBASE, Web of Science, and Global Index Medicus were searched for studies on AMR patterns in HAIs published from 01/2010 to 10/2020. Random-effects meta-analyses were performed to obtain pooled estimates. In total, 163 eligible studies were included in the review and meta-analysis. The pooled methicillin resistance proportion in <i>Staphylococcus aureus</i> was 48.4% (95% confidence interval [95%CI] 41·7-55·2, n = 80). Pooled carbapenem resistance proportions were high in Gram-negative pathogens: <i>Escherichia coli</i>: 16·6% (95%CI 10·7-23·4, n = 60); <i>Klebsiella pneumoniae</i>: 34·9% (95%CI 24·6-45·9, n = 50); <i>Pseudomonas aeruginosa</i>: 37.1% (95%CI 24·6-45·9, n = 56); <i>Enterobacter</i> spp.: 51·2% (95%CI 27·5-74·7, n = 7); and <i>Acinetobacter baumannii (complex):</i> 72·4% (95%CI 62·1-81·7%, n = 36). A higher resistance proportions were observed for third-generation cephalosporins: <i>Klebsiella pneumoniae</i>: 78·7% (95%CI 71·5-85·2, n = 46); <i>Escherichia coli:</i> 78·5% (95%CI 72·1-84·2%, n = 58); and <i>Enterobacter</i> spp.: 83·5% (95%CI 71·9-92·8, n = 8). We observed a high between-study heterogeneity (I<sup>2</sup>  &gt;  80%), which could not be explained by our set of moderators. Pooled resistance proportions for Gram-negative pathogens were higher in L-LMICs than regional and national estimates from HICs. Patients in resource-constrained regions are particularly affected by AMR. To combat the high resistance to critical antibiotics in L-LMICs, and bridge disparities in health, it is crucial to strengthen local surveillance and the health systems in general.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ayobami</LastName>
            <ForeName>Olaniyi</ForeName>
            <Initials>O</Initials>
            <Identifier Source="ORCID">0000-0003-1480-386X</Identifier>
            <AffiliationInfo>
              <Affiliation>Unit for Healthcare Associated Infections, Surveillance of Antimicrobial Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brinkwirth</LastName>
            <ForeName>Simon</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Unit for Healthcare Associated Infections, Surveillance of Antimicrobial Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eckmanns</LastName>
            <ForeName>Tim</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Unit for Healthcare Associated Infections, Surveillance of Antimicrobial Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Markwart</LastName>
            <ForeName>Robby</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0003-0338-3433</Identifier>
            <AffiliationInfo>
              <Affiliation>Unit for Healthcare Associated Infections, Surveillance of Antimicrobial Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jena University Hospital, Institute of General Practice and Family Medicine, Jena, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Emerg Microbes Infect</MedlineTA>
        <NlmUniqueID>101594885</NlmUniqueID>
        <ISSNLinking>2222-1751</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D040981" MajorTopicYN="Y">Acinetobacter baumannii</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003906" MajorTopicYN="Y">Developing Countries</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024881" MajorTopicYN="N">Drug Resistance, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007711" MajorTopicYN="N">Klebsiella pneumoniae</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antibiotic resistance</Keyword>
        <Keyword MajorTopicYN="N">Health equity</Keyword>
        <Keyword MajorTopicYN="N">hospital-acquired infections</Keyword>
        <Keyword MajorTopicYN="N">low-resource countries</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35034585</ArticleId>
        <ArticleId IdType="pmc">PMC8820817</ArticleId>
        <ArticleId IdType="doi">10.1080/22221751.2022.2030196</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ahmad M, Khan AU.. 
Global economic impact of antibiotic resistance: a review. J Glob Antimicrob Resist. 2019;19:313–316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31176071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tacconelli E, Carrara E, Savoldi A, et al. . 
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar;18(3):318–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29276051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabah A, Koulenti D, Laupland K, et al. . 
Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International cohort study. Intensive Care Med. 2012;38(12):1930–1945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23011531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laxminarayan R, Matsoso P, Pant S, et al. . 
Access to effective antimicrobials: a worldwide challenge. Lancet. 2016 Jan 9;387(10014):168–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26603918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allegranzi B, Bagheri Nejad S, Combescure C, et al. . 
Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011 Jan 15;377(9761):228–241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21146207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. . 
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Research ed)
2021;2021(372):n71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8005924</ArticleId>
            <ArticleId IdType="pubmed">33782057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Bank . World Bank country and lending groups 2021; 2021 Aug 20. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.</Citation>
        </Reference>
        <Reference>
          <Citation>Cochrane Community . Covidence 2020; 2020 Oct 23. Available from: https://community.cochrane.org/help/tools-and-software/covidence.</Citation>
        </Reference>
        <Reference>
          <Citation>Barendregt JJ, Doi SA, Lee YY, et al. . 
Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23963506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Houwelingen HC, Arends LR, Stijnen T.. 
Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002 Feb 28;21(4):589–624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11836738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Team RC . R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021 [cited 2021 August 24]. Available from: http://www.R-project.org.</Citation>
        </Reference>
        <Reference>
          <Citation>Guido Schwarzer JRC, Rücker G.. 
Meta-analysis with R. Springer International Publishing. Basel; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Viechtbauer W.
Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.</Citation>
        </Reference>
        <Reference>
          <Citation>Ahoyo TA, Bankole HS, Adeoti FM, et al. . 
Prevalence of nosocomial infections and anti-infective therapy in Benin: results of the first nationwide survey in 2012. Antimicrob Resist Infect Control. 2014;3. 10.1186/2047-2994-3-17</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2047-2994-3-17</ArticleId>
            <ArticleId IdType="pmc">PMC4039045</ArticleId>
            <ArticleId IdType="pubmed">24883183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labi AK, Obeng-Nkrumah N, Owusu E, et al. . 
Multi-centre point-prevalence survey of hospital-acquired infections in Ghana. J Hosp Infect. 2019;101(1):60–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29730140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agmy G, Mohamed S, Gad Y, et al. . 
Bacterial profile, antibiotic sensitivity and resistance of lower respiratory tract infections in upper Egypt. Mediterr J Hematol Infect Dis. 2013;5(1):1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3787711</ArticleId>
            <ArticleId IdType="pubmed">24106606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed F, Fayza F. Bacterial pattern and risk factors of hospital acquired infections in a tertiary care hospital, Egypt. 2018. p. 9–16.</Citation>
        </Reference>
        <Reference>
          <Citation>Amutha B, Viswanathan T.. 
Incidences of staphylococcus species in surgical site infections-prospective study from tertiary care center, Coimbatore. Tamilnadu. Int J Pharm Pharm Sci. 2015;7(5):225–228.</Citation>
        </Reference>
        <Reference>
          <Citation>Bhadade R, Harde M, desouza R, et al. . 
Emerging Trends of Nosocomial pneumonia in intensive care unit of a tertiary care public teaching hospital in Western India. Ann Afr Med. 2017;16(3):107–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5579893</ArticleId>
            <ArticleId IdType="pubmed">28671150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Sahrigy SAF, Shouman MG, Ibrahim HM, et al. . 
Prevalence and anti-microbial susceptibility of hospital acquired infections in two pediatric intensive care units in Egypt. Open Access Macedonian J Med Sci. 2019;7(11):1744–1749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6614260</ArticleId>
            <ArticleId IdType="pubmed">31316652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moemen D, Tawfeek D, Badawy W.. 
Healthcare-associated vancomycin resistant Enterococcus faecium; infections in the Mansoura University Hospitals intensive care units, Egypt. Braz j Microbiol. 2015;46(3):777–783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4568866</ArticleId>
            <ArticleId IdType="pubmed">26413060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Mekes A, Zahlane K, Said LA, et al. . 
The clinical and epidemiological risk factors of infections due to multi-drug resistant bacteria in an adult intensive care unit of University Hospital Center in Marrakesh-Morocco. J Infect Public Health. 2020;13(4):637–643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31537511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peters L, Olson L, Khu DTK, et al. . 
Multiple antibiotic resistance as a risk factor for mortality and prolonged hospital stay: a cohort study among neonatal intensive care patients with hospital-acquired infections caused by Gram-negative bacteria in Vietnam. Plos One. 2019;14(5).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6505890</ArticleId>
            <ArticleId IdType="pubmed">31067232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaari A, Mnif B, Bahloul M, et al. . 
Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int J Infect Dis. 2013;17(12):E1225–E1228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24094525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vijayanarayana K, Rau NR, Naik NA, et al. . 
An appraisal of sensitivity and resistance pattern of organisms isolated from hospital acquired pneumonia patients. research. J Pharm Biol Chem Sci. 2014;5(4):384–398.</Citation>
        </Reference>
        <Reference>
          <Citation>Klein EY, Van Boeckel TP, Martinez EM, et al. . 
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018;115(15):E3463–E3470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5899442</ArticleId>
            <ArticleId IdType="pubmed">29581252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Global antimicrobial resistance and use surveillance system (GLASS) report 2021. Geneva: WHO; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Antimicrobial resistance global report on surveillance: 2014 summary. World Health Organization. Geneva; 2014.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organisation . WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: WHO; 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Klein EY, Milkowska-Shibata M, Tseng KK, et al. . 
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data. Lancet Infect Dis. 2021;21(1):107–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32717205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mbwasi R, Mapunjo S, Wittenauer R, et al. . 
National consumption of antimicrobials in Tanzania: 2017-2019. Front Pharmacol. 2020;11:1667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7662556</ArticleId>
            <ArticleId IdType="pubmed">33192526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nordmann P, Naas T, Poirel L.. 
Global spread of carbapenemase-producing enterobacteriaceae. Emerg Infect Dis. 2011 Oct;17(10):1791–1798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3310682</ArticleId>
            <ArticleId IdType="pubmed">22000347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laxminarayan R, Duse A, Wattal C, et al. . 
Antibiotic resistance — the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–1098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24252483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox JA, Vlieghe E, Mendelson M, et al. . 
Antibiotic stewardship in low- and middle-income countries: the same but different?
Clin Microbiol Infect. 2017;23(11):812–818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28712667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broccoli MC, Pigoga JL, Nyirenda M, et al. . 
Essential medicines for emergency care in Africa. Afr J Emerg Med. 2018;8(3):110–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6223583</ArticleId>
            <ArticleId IdType="pubmed">30456159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tartari E, Tomczyk S, Pires D, et al. . 
Implementation of the infection prevention and control core components at the national level: a global situational analysis. J Hosp Infect. 2021;108:94–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7884929</ArticleId>
            <ArticleId IdType="pubmed">33271215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H, Yoon E-J, Kim D, et al. . 
Antimicrobial resistance of major clinical pathogens in South Korea, May 2016 to April 2017: first one-year report from Kor-GLASS. Eurosurveillance. 2018;23(42):1800047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6199864</ArticleId>
            <ArticleId IdType="pubmed">30352640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ham DC, See I, Novosad S, et al. . 
Investigation of hospital-onset methicillin-resistant Staphylococcus aureus bloodstream infections at eight high burden acute care facilities in the United States, 2016. J Hosp Infect. 2020 Apr 10;105:502–508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7857529</ArticleId>
            <ArticleId IdType="pubmed">32283173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Centre for Disease Prevention and Control . Antimicrobial resistance in the EU/EEA (EARS-Net): annual epidemiological report for 2019. Stockholm: ECDC; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Unni S, Siddiqui TJ, Bidaisee S.. 
Reduced Susceptibility and resistance to vancomycin of Staphylococcus aureus: a review of global Incidence patterns and related genetic mechanisms. Cureus. 2021;13(10):e18925–e18925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8603868</ArticleId>
            <ArticleId IdType="pubmed">34812309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention . Antibiotic resistance &amp; patient safety portal: antibiotic resistance. Atlanta: CDC; 2021 Aug 29; Available from: https://arpsp.cdc.gov/profile/antibiotic-resistance?tab = antibiotic-resistance.</Citation>
        </Reference>
        <Reference>
          <Citation>Japanese Ministry of Health Law . Japan Nosocomial Infections Surveillance (JANIS): annual open report 2020. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Liang Y, Qiu L, Zheng X, et al. . 
Trend in antimicrobial resistance of Staphylococcus aureus: results from the China Antimicrobial surveillance Network (CHINET) in the last 15-year-period reports (2005-2019). Infect Drug Resist. 2021;14:2179–2181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8203196</ArticleId>
            <ArticleId IdType="pubmed">34140786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayobami O, Willrich N, Reuss A, et al. . 
The ongoing challenge of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological analysis of bloodstream infections. Emerg Microbes Infect. 2020;9(1):1180–1193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7448851</ArticleId>
            <ArticleId IdType="pubmed">32498615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markwart R, Saito H, Harder T, et al. . 
Epidemiology and burden of sepsis acquired in hospitals and intensive care units: a systematic review and meta-analysis. Intensive Care Med. 2020 Aug;46(8):1536–1551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7381455</ArticleId>
            <ArticleId IdType="pubmed">32591853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brinkwirth S, Ayobami O, Eckmanns T, et al. . 
Hospital-acquired infections caused by enterococci: a systematic review and meta-analysis, WHO European region, 1 January 2010 to 4 February 2020. Eurosurveillance. 2021;26(45):2001628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8646982</ArticleId>
            <ArticleId IdType="pubmed">34763754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collignon P, Beggs JJ, Walsh TR, et al. . 
Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. The Lancet Planetary Health. 2018;2(9):e398–e405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30177008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphries RM, Abbott AN, Hindler JA.. 
Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories. J Clin Microbiol. 2019;57(6):e00203–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6535595</ArticleId>
            <ArticleId IdType="pubmed">30971460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Global action plan on antimicrobial resistance. Geneva; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Pan American Health Organization . Latin American network for antimicrobial resistance surveillance (RELAVRA): AMR trends analysis. Washington (DC: ): PAHO; 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Hu F, Zhu D, Wang F, et al. . 
Current status and trends of antibacterial resistance in China. Clin Infect Dis. 2018 Nov 13;67(suppl_2):S128–S134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30423045</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
